Reimbursement decision-making system in Poland systematically compared to other countries
Frontiers in Pharmacology · 13.10.2023 · 14
DOI: 10.3389/fphar.2023.1153680 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.10.2023. Verfasst von Aneta Mela und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Po…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Our objective was to analyze and compare systematically and structurally reimbursement systems in Poland and other countries.
Methods
The systems were selected based on recommendations issued by the Polish Agency for Health Technology Assessment and Tariffication (AHTAPol), which explicitly referred to other countries and agencies). Consequently, apart from Poland, the countries included in the analysis were England, Scotland, Wales, Ireland, France, Netherlands, Germany, Norway, Sweden, Canada, Australia and New Zealand. Relevant information and data were collected through a systematic search of PubMed (Medline), Embase and The Cochrane Library as well as competent authority websites and grey literature sources. Results and discussion: In most of the countries, the submission of a reimbursement application is initiated by a pharmaceutical company, and only a few countries allow it before a product is approved for marketing. All of the agencies analyzed are independent and some have regulatory function of reimbursement decision making body. A key criterion differentiating the various agencies in terms of HTA is the cost-effectiveness threshold. Most of the countries have specific mechanisms to improve access to expensive specialty drugs, including cancer drugs and those used for rare diseases. Reimbursement systems often lack consistency in appreciating the same stages, leading to heterogeneous decision-making processes. The analysis of recommendations issued in different countries for the same medicinal product will allow a better understanding of the relations between the reimbursement system, HTA assessment, stakeholders involvement and decision on reimbursement of innovative drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.
- Department of Administrative Proceedings, Faculty of Law and Administration, Marie Curie-Sklodowska University, Lublin, Poland.
- Department of Public Health, Medical University of Lublin, Lublin, Poland.
- Department of Orthopeadics and Rehabilitation, Medical University of Lublin, Lublin, Poland.
Zitieren
APA
Mela, A., Rdzanek, E., Jaroszyński, J., Furtak-Niczyporuk, M., Jabłoński, M., & Niewada, M. (2023). Reimbursement decision-making system in Poland systematically compared to other countries. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1153680
Vancouver
Mela A, Rdzanek E, Jaroszyński J, Furtak-Niczyporuk M, Jabłoński M, Niewada M. Reimbursement decision-making system in Poland systematically compared to other countries. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1153680
BibTeX
@article{Mela2023,
author = {Mela, Aneta and Rdzanek, Elżbieta and Jaroszyński, Janusz and Furtak-Niczyporuk, Marzena and Jabłoński, Mirosław and Niewada, Maciej},
title = {Reimbursement decision-making system in Poland systematically compared to other countries},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1153680}
}
EUVIMED